GLP-1 receptor agonists work by: Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps regulate blood sugar levels Slowing gastric emptying , meaning food remains in the stomach longer, promoting feelings of fullness Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger signals and food cravings Decreasing glucagon secretion , which helps prevent excessive glucose production by the liver Most GLP-1 agonists are administered via subcutaneous injection, typically once weekly or once daily depending on the specific formulation, though oral semaglutide (Rybelsus) is also available
Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ
595602, 2010 [20] Z
Overall, these therapies are relatively safe when performed by experienced providers, but patients should be informed of all possible complications, even if rare
The home is reorganizing itself around a different daily ritual
Both medications can begin reducing appetite early in treatment